Tien posters en vier presentaties geven de vooruitgang weer naar drievoudige combinatietherapie

Mechelen, België; 2 november 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) zal op de North American Cystic Fibrosis Conference (NACFC) 2017 vooruitgang laten zien in zowel het begrijpen van de mechanismen achter de compounds, als de klinische ontwikkeling van de brede portfolio van modulatoren. Galapagos zal de volgende plenaire voordrachten en posters presenteren in Indianapolis deze week:

Plenaire presentaties (alle tijden ET)

Donderdag 2 november
Voordracht W02: CFTR2017, 10:50 - 11:00 am
Katja Conrath - abstract #5, ACTIVITY OF HUMAN CFTR MODULATORS ON CFTR FROM DIFFERENT SPECIES
Voordracht TPS01: CFTR modulation & restoration, 9:45 - 11:05 am
Bertrand Kleizen (Utrecht University) - abstract #46, DECIPHERING THE MODE OF ACTION OF CLINICALLY RELEVANT NEXT GENERATION C2 CORRECTOR COMPOUNDS GLPG2737 AND GLPG3221 - flash poster presentatie

Vrijdag 3 november
Voordracht W18: Innovative approaches to CF therapies, 2:20 -2:30 am
Corina Balut - abstract #198, DEVELOPMENT AND CHARACTERIZATION OF NEXT-GENERATION CORRECTORS AS PART OF A TRIPLE CF THERAPY

Zaterdag 4 november
Voordracht W22: 11:05-11:15 am
Samantha DeStefano - abstract #13, EFFECTS OF N1303K MUTATION ON CFTR GATING

Poster presentaties

Poster #5
ACTIVITY OF HUMAN CFTR MODULATORS ON CFTR FROM DIFFERENT SPECIES, gepresenteerd door Katja Conrath

Poster #46
DECIPHERING THE MODE OF ACTION OF CLINICALLY RELEVANT NEXT GENERATION C2 CORRECTOR COMPOUNDS GLPG2737 AND GLPG3221, gepresenteerd door Bertrand Kleizen

Poster #36
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A NOVEL CFTR POTENTIATOR GLPG3067 IN HEALTHY VOLUNTEERS, gepresenteerd door Magdalena Petkova

Poster #259
GLPG1837 IN SUBJECTS WITH CYSTIC FIBROSIS AND THE S1251N OR G551D MUTATION: RESULTS FROM PHASE 2A STUDIES (SAPHIRA 1 AND 2), gepresenteerd door Katja Conrath

Poster #262
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES OF GLPG2737, A NOVEL CFTR CORRECTOR MOLECULE, IN HEALTHY VOLUNTEERS, gepresenteerd door Olivier van de Steen

Poster #263
PHARMACOKINETICS AND SAFETY OF A NOVEL CFTR CORRECTOR MOLECULE GLPG2222 IN HEALTHY SUBJECTS AND IN SUBJECTS WITH CYSTIC FIBROSIS: RESULTS FROM TWO PHASE I STUDIES, gepresenteerd door Olivier van de Steen

Poster #264
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF CFTR POTENTIATOR GLPG2451 WITH AND WITHOUT CFTR CORRECTOR GLPG2222 IN HEALTHY VOLUNTEERS, gepresenteerd door Gerben Van 't Klooster

Poster #31
STUDYING THE DISTINCT SENSITIVITIES OF CFTR MODULATORS USING ZEBRAFISH-CFTR, gepresenteerd door Onoftio Laselva

Poster #167
TESTING EFFICACY OF NOVEL CORRECTORS AND POTENTIATORS IN RESCUING A RARE CYSTIC FIBROSIS MUTATION BY FUNCTIONAL SCREENING OF A CRISPR/CAS9-ENGINEERED BRONCHIAL CELL LINE, gepresenteerd door Paul Eckford

Poster #27
MUTATIONS IN THE SECOND CYTOPLASMIC LOOP OF CFTR SUGGEST DISTINCT MODE OF ACTION BETWEEN POTENTIATORS VX-770 AND GLPG1837, gepresenteerd door Marjolein Mijnders

Poster #13
EFFECTS OF THE N1303K MUTATION ON CFTR GATING, gepresenteerd door Samantha DeStefano

Alle posters zullen kort na de presentatiesessies beschikbaar worden gemaakt op de Galapagos website, www.glpg.com.

Vanavond, donderdag 2 november van 8 uur tot 9 uur pm, organiseren we ons jaarlijkse IR event tijdens NACFC in het Conrad Hotel, 50 Washington St, Indianapolis. CSO Piet Wigerinck zal de hoofdlijnen van de NACFC presentaties presenteren en een update geven over ons CF programma. RSVP Elizabeth Goodwin, contactgegevens hieronder.

De North American Cystic Fibrosis Conference wordt gesponsord door de Cystic Fibrosis Foundation: www.cff.org

Voor meer informatie over cystic fibrosis: http://www.glpg.com/rd-cystic-fibrosis